Manuela Zanni
Overview
Explore the profile of Manuela Zanni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tucci A, Re A, Pagani C, Marcheselli L, Marcheselli R, Malaspina F, et al.
Leuk Lymphoma
. 2025 Mar;
:1-9.
PMID: 40055982
The FIL_RECANZ (ClinicalTrials.gov: NCT02371161) is a prospective study evaluating salvage with autologous stem cell transplantation (ASCT) in aggressive B-cell lymphoma patients aged 65 - 75, fit according to the FIL...
2.
Pulsoni A, Ferrero S, Tosti M, Luminari S, Dondi A, Cavallo F, et al.
Lancet Haematol
. 2024 Jun;
11(7):e499-e509.
PMID: 38937025
Background: The mainstay of treatment for early-stage follicular lymphoma is local radiotherapy, with a possible role for anti-CD20 monoclonal antibody (mAb). We aimed to evaluate the effect of these treatments...
3.
Stathis A, Pirosa M, Orsucci L, Feugier P, Tani M, Ghesquieres H, et al.
Haematologica
. 2024 Feb;
109(8):2564-2573.
PMID: 38385243
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC rituximab maintenance in patients with extranodal...
4.
Conconi A, Chiappella A, Ferreri A, Stathis A, Botto B, Sassone M, et al.
Blood Adv
. 2024 Jan;
8(6):1541-1549.
PMID: 38181782
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis...
5.
Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, Castellino A, Monaco F, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001657
We are currently witnessing a dramatic shift in our approach to the treatment of B-cell non-Hodgkin lymphoma (B-NHL). In the evolving clinical landscape, novel treatments for this clinically heterogeneous disease...
6.
Arcari A, Rigacci L, Tucci A, Puccini B, Usai S, Cavallo F, et al.
Blood Adv
. 2023 Jun;
7(15):4160-4169.
PMID: 37276080
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially...
7.
Tisi M, Moia R, Patti C, Evangelista A, Ferrero S, Spina M, et al.
Blood Adv
. 2023 May;
7(15):3916-3924.
PMID: 37171620
The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients...
8.
Catania G, Tavarozzi R, Pini G, Borra T, Gandolfo C, Zacchi G, et al.
J Basic Clin Physiol Pharmacol
. 2023 Apr;
34(3):401-404.
PMID: 37040263
Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic...
9.
Arcari A, Tabanelli V, Merli F, Marcheselli L, Merli M, Balzarotti M, et al.
Br J Haematol
. 2023 Feb;
201(4):653-662.
PMID: 36733229
Up to 10%-15% of diffuse large B-cell lymphoma (DLBCL) are related to hepatitis C virus (HCV) infection, in particular in elderly patients. The Fondazione Italiana Linfomi has recently published a...
10.
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai S, et al.
Leukemia
. 2023 Jan;
37(2):433-440.
PMID: 36653509
The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured....